Peer-reviewedCC BY-NC-ND 4.0Trials
Efficacy and safety of FXI antibody cenvacibart compared with aspirin for venous thromboprophylaxis in patients after total knee arthroplasty (ROXI-ASPEN): study protocol for a phase 3, double-blinded, randomized trial
Related
- Aspirin-Based Thromboprophylaxis Versus Anticoagulant Regimens After Total Hip or Knee Arthroplasty: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Efficacy of a smartphone digital therapeutic (re-R) for post-total knee arthroplasty rehabilitation: study protocol for a single-center randomized controlled trial in the Republic of Korea
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
- Safety and efficacy of lacnotuzumab, a colony-stimulating factor 1 antibody for the treatment of tenosynovial giant cell tumors: a randomized phase II trial
- Efficacy of real-time feedback exercise therapy in patients following total hip arthroplasty: a pilot cluster-randomized controlled trial
BibTeX
@article{kithcart2026efficacy,
title = {{Efficacy and safety of FXI antibody cenvacibart compared with aspirin for venous thromboprophylaxis in patients after total knee arthroplasty (ROXI-ASPEN): study protocol for a phase 3, double-blinded, randomized trial}},
author = {Aaron P. Kithcart and Margaret Onisko and Wanxue Zou and Siyu Li and José G. Raya and David E. Gutstein and Chase W. Smitterberg and ROXI-ASPEN Steering Committee and Michael A. Mont},
journal = {Trials},
year = {2026},
month = oct,
doi = {10.1186/s13063-026-10054-5},
url = {https://link.springer.com/article/10.1186/s13063-026-10054-5},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Efficacy and safety of FXI antibody cenvacibart compared with aspirin for venous thromboprophylaxis in patients after total knee arthroplasty (ROXI-ASPEN): study protocol for a phase 3, double-blinded, randomized trial
AU - Aaron P. Kithcart
AU - Margaret Onisko
AU - Wanxue Zou
AU - Siyu Li
AU - José G. Raya
AU - David E. Gutstein
AU - Chase W. Smitterberg
AU - ROXI-ASPEN Steering Committee
AU - Michael A. Mont
PY - 2026
DA - 2026/10/30
JO - Trials
DO - 10.1186/s13063-026-10054-5
UR - https://link.springer.com/article/10.1186/s13063-026-10054-5
SN - 1745-6215
ER -